NYU Study Finds Genetic Link Between GLP-1 Drugs and Male Hair Loss

Genetic susceptibility may help explain why some men taking GLP-1 weight-loss drugs report thinning hair. A study from NYU Langone Health found that men predisposed to androgenetic alopecia had a 7% higher risk of hair loss while using the drugs than men without that predisposition. The finding points to a possible difference in how patients respond, though it doesn't establish that GLP-1 medicines caused the hair loss or explain how large the effect might feel to an individual patient.

Genetics may shape the risk

Published in the Journal of Investigative Dermatology, the research analyzed genetic data from more than 200,000 men, most of them white. Men with androgenetic alopecia were more likely to have higher levels of GLP-1 receptor proteins. The researchers accounted for other hair-loss factors, including hypertension and high blood pressure, and still found the additional risk among men with the genetic predisposition.

That design gives the finding a specific focus: it links inherited susceptibility, receptor protein levels, and reported risk in a large group of men. But a genetic association isn't the same as a demonstration of cause and effect. The result suggests a possible connection that warrants further study; it doesn't show that higher receptor levels directly trigger hair loss during treatment, or that every man with the predisposition will experience thinning.

The 7% figure also needs careful reading. It describes a higher risk for one group relative to another in this analysis, not a guarantee that an individual will lose hair. The article doesn't provide an absolute risk, so readers can't use the percentage alone to estimate their personal likelihood. This is more significant than it looks as a research clue, but less definitive than a clinical prediction.

Hair loss has often been attributed to the rapid weight loss associated with drugs such as Ozempic, Wegovy and Zepbound. The NYU findings point to a possible direct genetic connection, though they don’t establish that the medication itself causes hair loss.

Those explanations aren't necessarily mutually exclusive. Changes in weight and a person's underlying genetic susceptibility could both matter, or the observed association could reflect factors the analysis hasn't resolved. The study raises a question about the role of GLP-1 receptors in hair loss; it doesn't settle whether the medicine, weight change, or their interaction is responsible.

“Our study provides the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically,” said senior investigator Lynn Petukhova, an assistant professor in dermatology and population health at NYU Grossman School of Medicine.

The researchers' description of a first genetic link marks the result as an early step. A link can help direct future research, but it doesn't by itself tell doctors what to recommend or patients what to expect. The distinction matters when a side effect is visible and personal, and when people may be weighing it against the reasons they take a weight-loss medicine.

What the findings could mean

The study focused on men, in part because more historical data is available on male hair loss. Women may also be affected, but the research doesn’t establish their risk.

That limitation leaves an important gap. Hair-loss patterns and the available records differ across populations, so results drawn mostly from men can't simply be applied to women. The same caution applies to the study's participant pool: because most participants were white, the findings may not describe risk equally well across groups with different backgrounds.

Petukhova said further experiments could help determine whether patients might be screened for hair-loss risk before receiving GLP-1 medications. She also described the possibility of combining GLP-1 treatment with hair-loss medicines such as minoxidil. For now, the findings identify a potential risk factor; they don’t show that screening or combination treatment prevents hair loss.

Screening would only be useful if researchers can establish what to screen for, how accurately it predicts hair loss, and whether the result changes care in a helpful way. The study points toward that line of inquiry, but it doesn't answer those practical questions. Likewise, naming minoxidil as a possible companion treatment isn't evidence that the combination has been tested or shown to work in this setting.

If you're working in this space, the next useful question is whether the association holds up in other groups and in research designed to clarify cause and timing. Patients, meanwhile, shouldn't read the finding as a personal forecast. A possible signal; not a verdict.

What remains unresolved

The study adds a genetic angle to a discussion often centered on weight loss itself. That shift could help researchers distinguish between hair changes associated with treatment, changes associated with losing weight, and pre-existing vulnerability. (And this is the part most people overlook: identifying a risk factor doesn't tell us whether acting on it will improve outcomes.)

For now, the evidence supports a narrow conclusion: among the men studied, genetic predisposition to androgenetic alopecia was associated with a modestly higher risk of hair loss while using GLP-1 drugs. It doesn't establish the mechanism, quantify the risk for an individual, or demonstrate that screening or adding another medicine would prevent hair loss. More research will determine whether this early genetic clue can be translated into clearer guidance for patients and clinicians.